Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 3,512 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Biospecimen Collection Clear all
Completed Phase 1 Interventional

Bisphenol A Controlled Exposure Study

NCT01573429
View directory record Official record
Conditions
Healthy Volunteers
Interventions
deuterated-Bisphenol A (d-BPA)
Other
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
25 Years to 45 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 17, 2026, 11:43 PM EDT
Completed No phase listed Observational

Changes in Cytokine Levels During an Acute Exacerbation of Chronic Obstructive Pulmonary Disease

NCT00281242
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive
Interventions
blood draw
Other
Lead sponsor
University of Michigan
Other
Eligibility
40 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 17, 2026, 11:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study

NCT00942136
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GSK1349572, Placebo, Omeprazole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2009 · Synced Oct 17, 2026, 11:43 PM EDT
Suspended Phase 1 Interventional

Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

NCT05993611
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder, Steroid Refractory Graft Versus Host Disease
Interventions
Biopsy, Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography, Echocardiography, Electronic Health Record Review, Leukapheresis, Lumbar Puncture, Magnetic Resonance Imaging, Quality-of-Life Assessment, Tafasitamab, X-Ray Imaging
Procedure · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 17, 2026, 11:43 PM EDT
Completed No phase listed Observational

Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer

NCT01546363
View directory record Official record
Conditions
Cervical Cancer
Interventions
Blood draw
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 17, 2026, 11:43 PM EDT
Completed Phase 2 Interventional Results available

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

NCT03513952
View directory record Official record
Conditions
Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma
Interventions
Atezolizumab, Biopsy, Biospecimen Collection, Computed Tomography, Glycosylated Recombinant Human Interleukin-7, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Positron Emission Tomography and Computed Tomography Scan
Drug · Procedure · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
9
States / cities
Riverside, California • Tampa, Florida • Honolulu, Hawaii + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 17, 2026, 11:43 PM EDT
Active, not recruiting Phase 1 Interventional

Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma

NCT04468841
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
cfDNA testing, sample of saliva or fingernail clipping, pre-treatment test specimen, PET/CT, CT, or MRI testing
Diagnostic Test · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 17, 2026, 11:43 PM EDT
Recruiting Phase 1 Interventional

Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas

NCT06964737
View directory record Official record
Conditions
Recurrent Malignant Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma, WHO Grade 2 Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma
Interventions
Anti-GARP Chimeric Antigen Receptor-T Cells, Biospecimen Collection, Chest Radiography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pheresis, Surgical Procedure
Biological · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 17, 2026, 11:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of ACH-0145228

NCT04709081
View directory record Official record
Conditions
Healthy
Interventions
ACH-0145228, Midazolam, Digoxin, Itraconazole
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 17, 2026, 11:43 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

NCT02224781
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
Interventions
Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Ipilimumab, Multigated Acquisition Scan, Nivolumab, Quality-of-Life Assessment, Trametinib Dimethyl Sulfoxide
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
838
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 528 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 17, 2026, 11:43 PM EDT
Not listed Not applicable Interventional

Immune Effects in Patients Treated With Whole Breast Irradiation

NCT03567044
View directory record Official record
Conditions
Breast Cancer
Interventions
Blood Draw
Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
45 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 17, 2026, 11:43 PM EDT
Active, not recruiting No phase listed Observational

Effects of Transitional Circulation in ELBW Infants

NCT02016599
View directory record Official record
Conditions
Neonatal Prematurity, Hypotension
Interventions
Monitoring and biospecimen collection
Other
Lead sponsor
University of Iowa
Other
Eligibility
Up to 1 Week
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 17, 2026, 11:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Normal Liver Stiffness by MR Elastography

NCT03235414
View directory record Official record
Conditions
Liver Diseases
Interventions
MRI, Blood draw
Device · Diagnostic Test
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 17, 2026, 11:43 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Specimen and Data Collection in South Carolina Medicaid-Enrolled Patients With Type 2 Diabetes (T2D) and Metabolically Healthy Controls

NCT07731399
View directory record Official record
Conditions
Type 2 Diabetes, Healthy (Controls)
Interventions
Not applicable- observational study
Other
Lead sponsor
Guardian Research Network, Inc.
Other
Eligibility
40 Years to 70 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
Orangeburg, South Carolina • Walhalla, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 17, 2026, 11:43 PM EDT
Recruiting No phase listed Observational

Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

NCT06580106
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Biospecimen samples
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 17, 2026, 11:43 PM EDT
Recruiting Phase 1 Interventional

Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation

NCT06735664
View directory record Official record
Conditions
Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma
Interventions
Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography, Multigated Acquisition Scan, Odronextamab, Positron Emission Tomography, Ultrasound Imaging, Zanubrutinib
Procedure · Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 17, 2026, 11:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

VIDAS® NEPHROCLEAR Reference Interval Study

NCT06037109
View directory record Official record
Conditions
Healthy
Interventions
Diagnostic Test: VIDAS® NEPHROCLEAR™ CCL14 Test
Device
Lead sponsor
BioMérieux
Industry
Eligibility
21 Years and older
Enrollment
585 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 17, 2026, 11:43 PM EDT
Recruiting Phase 2 Interventional

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

NCT06029270
View directory record Official record
Conditions
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Carboplatin, Cisplatin, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Relatlimab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
83
States / cities
Dublin, California • Fremont, California • Fresno, California + 62 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 11:43 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Validation of Point of Care Liver Function Tests

NCT03800069
View directory record Official record
Conditions
Liver Diseases, Healthy, Cirrhosis, Liver, Fibrosis
Interventions
Group K Diagnostic point of care device
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 17, 2026, 11:43 PM EDT
Terminated No phase listed Observational

Identification of Key Blood Molecular Markers for Immunotherapy

NCT00507702
View directory record Official record
Conditions
Squamous Cell Carcinoma, Adenocarcinoma, Neoplasms
Interventions
phlebotomy
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 17, 2026, 11:43 PM EDT
Completed No phase listed Observational

Tissue Sample Collection From Patients With Fanconi Anemia

NCT00899522
View directory record Official record
Conditions
Fanconi Anemia, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
biologic sample preservation procedure, biopsy
Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
1 Year to 55 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Oct 17, 2026, 11:43 PM EDT
Terminated No phase listed Observational

Circulating Tumor Cells in Prostate Cancer Patients

NCT01414712
View directory record Official record
Conditions
Prostate Cancer
Interventions
Blood Drawing
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 17, 2026, 11:43 PM EDT
Recruiting Phase 1Phase 2 Interventional

DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer

NCT07705919
View directory record Official record
Conditions
Borderline Resectable Pancreatic Ductal Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Fluorouracil, Gadolinium-Chelate, Gemcitabine, Irinotecan, Leucovorin Calcium, Nab-paclitaxel, Oxaliplatin, Point-of-care portable perfusion phantom (P4)
Procedure · Drug · Device
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 17, 2026, 11:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study to Assess Outcomes in Women Undergoing Either Hysteroscopic Sterilization (Essure®) or Laparoscopic Tubal Sterilization

NCT03127722
View directory record Official record
Conditions
Contraception
Interventions
Blood draw, ESSURE (BAY1454032), Laparoscopic tubal sterilization
Procedure · Device
Lead sponsor
Bayer
Industry
Eligibility
21 Years and older · Female only
Enrollment
990 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
57
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 17, 2026, 11:43 PM EDT